Study suggests CBD "potent anti-tumor drug" in treatment of breast cancer

Enfleur-blog-cancer-study-cbd_01.png

ENFLEUR is excited to promote a study that demonstrates that by modulation of the tumor microenvironment, CBD is able to inhibit both breast cancer growth and metastasis, including triple negative breast cancer (TNBC). Published in Molecular Oncology, an international journal directed towards new discoveries, approaches, and technical developments in cancer research, the study is the first to show that CBD significantly inhibits the proliferation of breast cancer cells that are epidermal growth factor (EGF)-induced. CBD was also shown to significantly inhibit chemotaxis of breast cancer cells, an essential component of tumor spreading. Cannabinoids have been used in cancer therapy prior to this study due to their anti-inflammatory, apoptotic, and cell growth inhibition effects, as well as their ability to modulate pain. This study adds finding that suggest that by suppressing tumor cell proliferation, CBD has the potential to impede tumor growth.

CBD has come to light as an effective anti-anxiety, and has demonstrated notable anti-inflammatory activity. Since it is well-tolerated, even at acute doses, incorporating high quality and high potency CBD into a wellness routine is a matter worth serious consideration.

Why does this matter? The results of this study contribute to cannabinoids’ profile as a promising cancer therapy by suggesting that CBD is “a potent anti-tumor drug with anti-proliferative, anti-migratory, and anti-invasive properties”.